{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:21:59Z","timestamp":1747200119233,"version":"3.40.5"},"reference-count":6,"publisher":"Media Sphere Publishing House","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. nevrol. psikhiatr. im. S.S. Korsakova"],"published-print":{"date-parts":[[2022]]},"DOI":"10.17116\/jnevro202212207273","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T08:17:11Z","timestamp":1659341831000},"page":"73","source":"Crossref","is-referenced-by-count":1,"special_numbering":"Vyp. 2","title":["Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis"],"prefix":"10.17116","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2975-4151","authenticated-orcid":false,"given":"A.N.","family":"Boyko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"doi-asserted-by":"crossref","unstructured":"Dobson R, Giovannoni G. Multiple sclerosis. Eur J Neurology. 2019;26(1):27-40","key":"key-10.17116\/jnevro202212207273-1","DOI":"10.1111\/ene.13819"},{"unstructured":"Gusev EI, Boyko AN. Multiple sclerosis. Zdorovie Cheloveka. 2021;1:97-113. (In Russ.)","key":"key-10.17116\/jnevro202212207273-2"},{"doi-asserted-by":"crossref","unstructured":"Giovannoni G, Comi G, Cook S, et al. CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. NEJM. 2010;362(5):416-426","key":"key-10.17116\/jnevro202212207273-3","DOI":"10.1056\/NEJMoa0902533"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202212207273-4","DOI":"10.1007\/s40263-018-0562-0"},{"doi-asserted-by":"crossref","unstructured":"Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscipl Healthcare. 2018;11:295-300","key":"key-10.17116\/jnevro202212207273-5","DOI":"10.2147\/JMDH.S160029"},{"doi-asserted-by":"crossref","unstructured":"Butzkueven H, Spelman T, Ozakbas S, et al. and MSBase Study Group. Real-world Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry. AAN. 2022;P12-4.003","key":"key-10.17116\/jnevro202212207273-6","DOI":"10.1212\/WNL.98.18_supplement.1373"}],"container-title":["Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T10:57:29Z","timestamp":1727693849000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova-2\/2022\/7-2\/1199772982022072073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":6,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"alternative-id":["10.17116\/jnevro202212207273"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202212207273","relation":{},"ISSN":["1997-7298"],"issn-type":[{"type":"print","value":"1997-7298"}],"subject":[],"published":{"date-parts":[[2022]]}}}